Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Casein phosphopeptide-amorphous calcium phosphate (CPP-ACP) is a remineralizing dental treatment derived from milk casein. The casein phosphopeptides (CPP) stabilize high concentrations of calcium and phosphate ions in an amorphous, non-crystalline state (ACP), creating a reservoir of bioavailable minerals. When applied topically to teeth, CPP-ACP binds to dental biofilm and enamel, maintaining a supersaturated environment that promotes the remineralization of subsurface enamel lesions and inhibits demineralization. It is widely used to treat white spot lesions, particularly those occurring after orthodontic therapy, and to manage dentin hypersensitivity. The technology was originally developed at the University of Melbourne and is marketed under the trade name Recaldent.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on casein phosphopeptide-amorphous calcium phosphate (University of Melbourne).